David Nierengarten
Stock Analyst at Wedbush
(4.38)
# 311
Out of 5,152 analysts
215
Total ratings
53.67%
Success rate
16.99%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TCRX TScan Therapeutics | Maintains: Outperform | $4 → $5 | $1.13 | +342.48% | 5 | Mar 5, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $90 → $95 | $70.92 | +33.95% | 4 | Mar 3, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 → $65 | $25.52 | +154.70% | 4 | Feb 25, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $50 → $53 | $46.02 | +15.17% | 6 | Feb 25, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $13.85 | +44.40% | 10 | Feb 24, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Underperform | $110 | $112.70 | -2.40% | 1 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Outperform | $110 → $88 | $60.34 | +45.84% | 5 | Feb 17, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.57 | +140.70% | 12 | Feb 10, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $5.10 | +115.69% | 5 | Jan 30, 2026 | |
| COGT Cogent Biosciences | Reiterates: Outperform | $55 | $37.46 | +46.82% | 4 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $20.95 | +47.97% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $18 | $14.23 | +26.49% | 9 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $728.11 | +37.34% | 24 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $18.50 | +62.16% | 3 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $9.97 | +150.75% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $7 | $13.15 | -46.77% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $1.38 | +407.25% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $115 | $100.13 | +14.85% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4 | $5.10 | -21.57% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $11.16 | +132.97% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.13 | +208.56% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $14.56 | -45.05% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $22.50 | -11.11% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $57.28 | -30.17% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $46.15 | +1.84% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $33.17 | +20.59% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $40.59 | +10.86% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.74 | +213.59% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.93 | +205.34% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.31 | +21,545.02% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $8.82 | +580.27% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.93 | +139.60% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $21.46 | +249.49% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.12 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.93 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.46 | - | 3 | Nov 20, 2017 |
TScan Therapeutics
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.13
Upside: +342.48%
Apogee Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $70.92
Upside: +33.95%
Beam Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $25.52
Upside: +154.70%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Outperform
Price Target: $50 → $53
Current: $46.02
Upside: +15.17%
ORIC Pharmaceuticals
Feb 24, 2026
Reiterates: Outperform
Price Target: $20
Current: $13.85
Upside: +44.40%
ABIVAX Société Anonyme
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $112.70
Upside: -2.40%
Disc Medicine
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $60.34
Upside: +45.84%
Nuvation Bio
Feb 10, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.57
Upside: +140.70%
Perspective Therapeutics
Jan 30, 2026
Reiterates: Outperform
Price Target: $11
Current: $5.10
Upside: +115.69%
Cogent Biosciences
Jan 21, 2026
Reiterates: Outperform
Price Target: $55
Current: $37.46
Upside: +46.82%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $20.95
Upside: +47.97%
Jan 15, 2026
Reiterates: Neutral
Price Target: $18
Current: $14.23
Upside: +26.49%
Jan 14, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $728.11
Upside: +37.34%
Jan 13, 2026
Reiterates: Outperform
Price Target: $30
Current: $18.50
Upside: +62.16%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $9.97
Upside: +150.75%
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $13.15
Upside: -46.77%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.38
Upside: +407.25%
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $100.13
Upside: +14.85%
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $5.10
Upside: -21.57%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $11.16
Upside: +132.97%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $7.13
Upside: +208.56%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $14.56
Upside: -45.05%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $22.50
Upside: -11.11%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $57.28
Upside: -30.17%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $46.15
Upside: +1.84%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $33.17
Upside: +20.59%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $40.59
Upside: +10.86%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $5.74
Upside: +213.59%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.93
Upside: +205.34%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.31
Upside: +21,545.02%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $8.82
Upside: +580.27%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.93
Upside: +139.60%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $21.46
Upside: +249.49%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.93
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.46
Upside: -